Zevra Therapeutics (ZVRA) CEO sale and RSU vesting under 10b5-1 plan

Rhea-AI Filing Summary

Zevra Therapeutics President and CEO Neil F. McFarlane reported equity award vesting and a planned share sale. On February 7, 2026, 37,500 restricted stock units vested, converting into the same number of common shares as part of an award that vests in three annual installments.

On February 9, 2026, McFarlane sold 14,625 shares of common stock at a weighted average price of $8.5597 per share under a pre-arranged Rule 10b5-1(c) trading plan adopted on March 21, 2025. Following these transactions, he directly holds 387,225 common shares and 75,000 restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McFarlane Neil F.

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/07/2026		M		37,500	A	(1)	401,850	D
Common Stock	02/09/2026		S(2)		14,625	D	$8.5597(3)	387,225	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	02/07/2026		M			37,500	(4)	(4)	Common Stock	37,500	$0	75,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Adoption date of referenced 10b5-1(c) plan is: 3/21/2025.

3. This transaction was executed in multiple trades at prices ranging from $8.39 to $8.67. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

4. One third of the restricted stock units vested and settled on February 7, 2026. The remaining two thirds of the shares will vest and settle in two equal annual installments thereafter, subject in each case to the Reporting person's continued service through such vesting date.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Neil F. McFarlane	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did ZVRA CEO Neil McFarlane report?

Neil McFarlane reported RSU vesting and a share sale. On February 7, 2026, 37,500 restricted stock units vested into common stock. On February 9, 2026, he sold 14,625 common shares at a weighted average price of $8.5597 per share.

How many Zevra Therapeutics (ZVRA) shares did the CEO sell and at what price?

The CEO sold 14,625 ZVRA common shares. The sale on February 9, 2026 was executed in multiple trades at prices between $8.39 and $8.67, with a reported weighted average sale price of $8.5597 per share.

Was the ZVRA CEO’s stock sale made under a 10b5-1 trading plan?

Yes, the stock sale was under a 10b5-1(c) plan. A footnote states the referenced Rule 10b5-1(c) trading plan was adopted on March 21, 2025, and the February 9, 2026 sale was executed pursuant to that pre-arranged plan.

How many Zevra Therapeutics (ZVRA) shares does the CEO own after these transactions?

After the reported transactions, the CEO directly owns 387,225 common shares. He also holds 75,000 restricted stock units, each representing a contingent right to receive one share of Zevra Therapeutics common stock, subject to future vesting conditions.

What happened to the CEO’s restricted stock units in this ZVRA Form 4?

One-third of the CEO’s restricted stock units vested. On February 7, 2026, 37,500 RSUs vested and settled into common stock. The remaining two-thirds vest in two equal annual installments, subject to his continued service through each vesting date.

What does each ZVRA restricted stock unit reported by the CEO represent?

Each restricted stock unit equals one share of common stock. A footnote clarifies that every RSU represents a contingent right to receive one share of Zevra Therapeutics’ common stock upon vesting and settlement, assuming the applicable service-based vesting conditions are met.